Your AI-Trained Oncology Knowledge Connection!
The pharmacologic treatment for advanced renal cell carcinoma has evolved considerably since the FDA approved interleukin-2 as the first systemic therapy for the tumor type in 1992. Since then, the FDA has approved more than 20 drugs for RCC in the past 12 years.
Twelve creative and influential oncology research leaders are the winners of the 2017 Giants of Cancer Care® awards, a unique honor that recognizes physician-scientists who have helped move cancer care forward.
Lurbinectedin (PM01183 or PM1183), a transcription inhibitor that induces DNA double-strand breaks, is being combined with doxorubicin in a phase III trial for patients with recurrent small cell lung cancer in the hopes of providing a superior option to the current standard-of-care second-line chemotherapy.
Jeff Sharman, MD, discusses the prospects for progress in targeting elements of the BCR pathway.
Updates to the National Comprehensive Cancer Network guidelines for the management of advanced non–small cell lung cancer call for routine molecular analysis and testing for PD-L1 expression, preferably at diagnosis.
Updated guidelines for the management of invasive breast cancer, issued by the National Comprehensive Cancer Network, define indications for radiation therapy, the use of biomarkers and multigene assays in clinical decision making, and new concepts in endocrine therapy in early-stage and advanced-stage estrogen receptor-positive breast cancer.
Less than 2 years after checkpoint blockade immunotherapy first became available for patients with non-small cell lung cancer, the PD-1 inhibitor pembrolizumab is poised to reshape the treatment paradigm for previously untreated individuals without molecular mutations.
Jonathan C. Trent, MD, PhD, discusses Sylvester Comprehensive Cancer Center’s ongoing efforts to advance the precision medicine process to improve patient care.
Foundation Focus CDx BRCA, can detect both germline and somatic BRCA1/2 mutations in women with ovarian cancer who are candidates for the PARP inhibitor rucaparib (Rubraca).
The National Comprehensive Cancer Network published its first set of guidelines for myeloproliferative neoplasms in October 2016 and is already looking to update and expand these guidelines.
Despite the availability of numerous effective treatment options, most patients with B-cell malignancies still experience frequent relapses and progressively shorter remissions, creating a pressing need for new drugs to add to the therapeutic arsenal.
Randomization designed to isolate the impact of a specific factor has enabled practitioners to understand the value, or lack of value of particular drugs, procedures, or processes in a given clinical setting.
